Page 2 - Myopia Control News Today : Breaking News, Live Updates & Top Stories | Vimarsana

- MyopiaX-1 trial to generate first clinical evidence with MyopiaX®, a novel therapeutic approach to manage myopia progression- First data readout expected...

“Everyone has noticed that it seems like the kids are becoming nearsighted faster than they used to,” says Dr. Grace Prakalapakorn at the Duke Eye Center.

“Everyone has noticed that it seems like the kids are becoming nearsighted faster than they used to,” says Dr. Grace Prakalapakorn at the Duke Eye Center.

SEATTLE--(BUSINESS WIRE)--Kubota Vision Inc. (“Kubota Vision” or the “Company”), a clinical-stage specialty ophthalmology company and a wholly owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Tokyo 4596), announced today the execution of a collaborative research agreement between Kubota Vision and China...

Use of low-dose atropine eyedrops (concentration 0.01%) was no better than placebo at slowing myopia (nearsightedness) progression and elongation of the eye among children treated for two years, according to a randomized controlled trial conducted by the Pediatric Eye Disease Investigator Group (PEDIG) and funded by the National Eye Institute (NEI). The trial aimed to identify an effective way to manage this leading and increasingly common cause of refractive error, which can cause serious uncorrectable vision loss later in life. Results from the trial were published in JAMA Ophthalmology.